City of Industry, CA -- (SBWIRE) -- 06/28/2018 -- This report studies the global Plasminogen market status and forecast, categorizes the global Plasminogen market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF).

The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen).

Request Sample Copy of the Report @  https://www.qyresearch.com/sample-form/form/215529/global-plasminogen-sales-market

Currently, the product has obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). Clinical trials are still underway to obtain Marketing Authorization in the United States and in Europe (EU). The report mainly targeting the research status, predicted competitive landscape, market potential and future trends of plasminogen market.

Plasminogen was originally used as an orphan drug for the treatment of congenital plasminogen deficiency, but the researchers found that he had positive effects on wound care and Diabetic Foot Ulcer treatment. And there is hope that the amputation costs and pain of such patients will be greatly reduced. Once FDA certification is available in the Diabetic Foot Ulcer area, it will benefit significantly from the 10 billion USD amputation market.

China's demand is the biggest and the most direct in the entire potential market. The main reason is that China's gradual growth in per capita consumption and has a relatively good medical system. In addition, China has the largest number of people with diabetes in the world. The market demand is obvious.

If it only acts as an orphan drug, it had almost no development prospects and market, with Congenital Plasminogen Deficiency as an example, the global prevalence around 10 thousand people, we expect 2000-3000 of these people may use the drugs, but the income is far less than the R & D expenditure. But the research team is optimistic about its potential use, especially in wound care and Diabetic Foot Ulcer treatment.

The global Plasminogen market is valued at 11400 million US$ in 2017 and will reach 16500 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2018-2025.

Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/215529/global-plasminogen-sales-market

The major players covered in this report

Kedrion

Prometic

Genentech (Roche)

Boehringer Ingelheim

Kyowa Hakko Kirin

Omeros Corporation

...

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States

Europe

China

Japan

Southeast Asia

India